Medication info
Diapolmin XR Tablets 500mg (Metformin Hydrochloride)

Diapolmin XR Tablets 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewong Bio Co., Ltd.
Appearance
White rectangular extended-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201603574 · Approved 2016.06.17 · Insurance code 694001240

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dosage should be determined individually based on efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the starting dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking 2000mg or more of immediate-release metformin per day. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to treatment with this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Daewong Bio Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This drug is used for adult patients with type 2 diabetes who have difficulty controlling blood sugar levels with diet and exercise alone, particularly those who are overweight. It helps effectively control blood sugar levels when used alone or in combination with other oral hypoglycemic agents or insulin. By doing so, it contributes to the stable management of blood sugar levels and prevention of complications. This drug plays an important role in diabetes management by enabling tailored treatment according to the patient's health status. It is widely used for the treatment of type 2 diabetes.

How to take

Adult dose

The dosage should be determined individually based on efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the starting dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking 2000mg or more of immediate-release metformin per day. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to treatment with this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Precautions

This drug can rarely cause a serious condition called lactic acidosis; therefore, if symptoms of lactic acidosis occur, immediate medical attention should be sought. If taken with other diabetes medications, hypoglycemia may occur, so blood sugar levels should be closely monitored. Patients with moderate or severe renal impairment, dehydration, serious infections, or heart problems should not take this drug. Particularly, this drug should be discontinued before and after tests using radiocontrast agents and should be resumed only after checking renal function. It should not be administered to patients with an allergy to this drug or to those with type 1 diabetes or acute metabolic acidosis such as diabetic ketoacidosis. In cases of severe infections or major surgeries, this drug should be temporarily discontinued and resumed after recovery. Patients with poor nutritional status, liver function disorders, respiratory issues, or excessive alcohol consumption should use this drug cautiously. Pregnant women at risk of placental insufficiency or preeclampsia should avoid using this drug, and careful monitoring of fetal growth is required if used during pregnancy. The safety and efficacy of this drug have not been established in children, and it is not recommended for those under 17 years of age. Elderly patients should have regular renal function tests due to the risk of renal impairment and adjust the dosage accordingly. Side effects may include gastrointestinal disturbances, taste disorders, vitamin B12 deficiency, and rarely, skin rashes or allergic reactions. Taking this drug with food may reduce gastrointestinal disturbances, and it should be swallowed whole without crushing or chewing the tablets. Since this drug may interact with other medications, especially hypoglycemic agents, diuretics, or antihypertensive drugs, consultation with a physician is advised when taking them together. Alcohol may increase the risk of adverse effects from this drug, so excessive drinking should be avoided. If pregnant or breastfeeding, consultation with a healthcare provider regarding the use of this drug is essential, and if breastfeeding, consideration should be given to stopping breastfeeding or ceasing drug therapy. In the case of overdose, hypoglycemia does not usually occur, but the drug may accumulate in the body, thus immediate medical treatment should be sought. This drug should be stored out of the reach of children and should not be transferred to another container.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent exposure to air or moisture, ideally at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

White rectangular extended-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.